Clinical Trials Logo

Plasma Cell Disorder clinical trials

View clinical trials related to Plasma Cell Disorder.

Filter by:
  • None
  • Page 1

NCT ID: NCT06330896 Not yet recruiting - Clinical trials for Plasma Cell Disorder

Disease Characteristics and Treatment Response in Plasma Cell Disorders Patients Based on Genetic Abnormalities From Fluorescence In Situ Hybridization and Next Generation Sequencing

genetics MM
Start date: April 1, 2024
Phase:
Study type: Observational

The goal of this observational study is to study the genetic landscape in patients with Plasma Cell Disorders including MGUS, SMM, MM, and amyloidosis in Thailand. The main questions it aims to answer are: - genetic landscape in patients with Plasma Cell Disorders including MGUS, SMM, MM, and amyloidosis in Thailand who were performed FISH and/or NGS testing - genetic correlation and genetic dependency between FISH and NGS, stratified by high- and standard-risk groups based on FISH testing in Thai MM patients. - disease characteristics and response rates in MM patients with cytogenetic abnormalities detected by FISH and/or genetic mutations detected by NGS. - correlation between cytogenetic abnormalities identified by FISH and genetic mutations detected by NGS with progression-free survival in MM patients. The FISH and/or NGS testing results, disease characteristics, treatment, and treatment outcomes of patients with plasma cell disorders who underwent FISH and/or NGS testing before IRB approval will be collected through retrospective chart review. Subsequently, data will be gathered prospectively. Participants will provide approximately 12 mL of bone marrow fluid for FISH and NGS testing.

NCT ID: NCT06313502 Not yet recruiting - Clinical trials for Plasma Cell Disorder

High Dose Ascorbic Acid (HDAA) in Patients With Plasma Cell Disorders

Start date: June 2024
Phase: Phase 1
Study type: Interventional
Read more »
NCT ID: NCT05032339 Completed - Clinical trials for Plasma Cell Disorder

Evaluation of the Plasma Cell Disorders Panel on the BD FACSLyric™ Flow Cytometer

Start date: May 4, 2021
Phase:
Study type: Observational

Multi-site, prospective performance study to determine equivalency between the investigational OneFlow PCD panel on the FACSLyric system versus the final clinical diagnosis.

NCT ID: NCT04879043 Recruiting - Multiple Myeloma Clinical Trials

Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma

Start date: February 7, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This study will assess the safety, tolerability, pharmacokinetics (PK) and the therapeutic potential of HDP-101 in patients with plasma cell disorders including multiple myeloma.

NCT ID: NCT03480360 Active, not recruiting - Lymphoma Clinical Trials

Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression

Start date: March 28, 2018
Phase: Phase 3
Study type: Interventional

The standard Johns Hopkins' regimen will be used in study subjects, with the use of donor peripheral blood stem cells, rather than marrow. Clinical outcomes will be defined while focusing efforts on immune reconstitution focusing on immune checkpoint regulators after a related haploidentical stem cell transplant.

NCT ID: NCT02274519 Completed - Multiple Myeloma Clinical Trials

Novel Support Options in Autologous Stem Cell Transplant for Multiple Myeloma

Start date: February 2015
Phase: N/A
Study type: Interventional

Does Tai Chi Easy (TCEasy), a simple and repetitive form of exercise that consists of movements with meditation, improve quality of life in those afflicted with multiple myeloma undergoing autologous stem cell transplantation?

NCT ID: NCT02041325 Active, not recruiting - Clinical trials for Plasma Cell Disorder

Investigation of the Enhancement of the Response to Hepatitis B Vaccine by Lenalidomide (RevlimidTM, CC-5013) in Plasma Cell Dyscrasias

Start date: April 2005
Phase: Phase 2
Study type: Interventional
Read more »